COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,198 Articles (22,713 medRxiv, 8,485 bioRxiv)

Most recent first Previous |  Page 1062: Articles 10611-10620  | Next

Genomic determinants of Furin cleavage in diverse European SARS-related bat coronaviruses
Sander, A.-L., Moreira-Soto, A., Yordanov, S., Toplak, I., Balboni, A., Ameneiros, R. S., Corman, V. M., Drosten, C., Drexler, J. F.
10.1101/2021.12.15.472779 — Posted: 2021-12-15
Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein
Yamamoto, M., Gohda, J., Kobayashi, A., Tomita, K., Hirayama, Y., Koshikawa, N., Seiki, M., Semba, K., Akiyama, T., Kawaguchi, Y., Inoue, J.-i.
10.1101/2021.12.14.472513 — Posted: 2021-12-15
Booster of mRNA-1273 Vaccine Reduces SARS-CoV-2 Omicron Escape from Neutralizing Antibodies
Doria-Rose, N., Shen, X., Schmidt, S. D., O'Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., Tang, H., Atmar, R. L., Lyke, K. E., Wang, L., Zhang, y., Gaudinski, M. R., Black, W. P., Gordon, I., Guech, M., Ledgerwood, J. E., Misasi, J. N., Widge, A., Roberts, P. C., Beigel, J., Korber, B., Pajon, R., Mascola, J. R., Montefiori, D. C.
10.1101/2021.12.15.21267805 — Posted: 2021-12-15 Discussion: Onsite
SARS-CoV-2 Omicron: reduction of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
Aggarwal, A., Ospina Stella, A., Walker, G., Akerman, A., Milogiannakis, V., Hoppe, A. C., Mathivanan, V., Fichter, C., McAllery, S., Amatayakul-Chantler, S., Roth, N., Coppola, G., Munier, M. L., Darley, D. R., Khoury, D. S., Foster, C. S. P., Lu, Y., Schofield, P., Jackson, J., Henry, J., Mazigi, O., Jaeck, H.-M., Langles, D., Cromer, D., Davenport, M. P., Christ, D., Matthews, G., Rawlinson, W., Kelleher, A. D., Turville, S. G.
10.1101/2021.12.14.21267772 — Posted: 2021-12-15
Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study
Evans, R. A., Leavy, O. C., Richardson, M., Elneima, O., McAuley, H. J. C., Shikotra, A., Singapuri, A., Sereno, M., Saunders, R. M., Harris, V. C., Aul, R., Beirne, P., Bolton, C. E., Brown, J. S., Choudhury, G., Diar Bakerly, N., Easom, N., Echevarria, C., Fuld, J., Hart, N., Hurst, J. R., Jones, M., Parekh, D., Pfeffer, P., Rahman, N. M., Rowland-Jones, S., Shah, A. M., Wootton, D. G., Chalder, T., Davies, M. J., De Soyza, A., Greenhalf, W., Greening, N. J., Heaney, L. G., Heller, S., Howard, L., Jacob, J., Jenkins, R. G., Lord, J. M., Man, W. D.-C., McCann, G. P., Neubauer, S., Openshaw, P. J., Porter, J., Quint, J., Rowland, M. J., Scott, J., Semple, M. G., Singh, S. J., Toshner, M., Lewis, K., Briggs, A., Docherty, A. B., Kerr, S., Lone, N. I., Sheikh, A., Thorpe, M., Zheng, B., Chalmers, J. D., Ho, L.-P., Horsley, A., Marks, M., Poinasamy, K., Raman, B., Harrison, E. M., Wain, L. V., Brightling, C. E., PHOSP-COVID Collaborative Group
10.1101/2021.12.13.21267471 — Posted: 2021-12-15
In silico evidence of superantigenic features in ORF8 protein from COVID-19
Gomez-Icazbalceta, G., Hussain, Z., Velez-Alavez, M.
10.1101/2021.12.14.472240 — Posted: 2021-12-14
Potential cross-protection against SARS-CoV-2 from previous exposure to bovine coronavirus
Querne, L. B. P., Bastos, F. Z., Beirao, B. C. B.
10.1101/2021.12.13.472476 — Posted: 2021-12-14
SARS-CoV-2 T cell responses are expected to remain robust against Omicron
Ahmed, S. F., Quadeer, A. A., McKay, M.
10.1101/2021.12.12.472315 — Posted: 2021-12-14
Genomics-informed outbreak investigations of SARS-CoV-2 using civet
O'Toole, A. N., Hill, V., Jackson, B., Dewar, R., Sahadeo, N., Colquhoun, R., Rooke, S., McCrone, J. T., McHugh, M., Nicholls, S., Poplawski, R., The COVID-19 Genomics UK (COG-UK) Consortium, , COVID-19 Impact Project (Trinidad & Tobago Group), , Aanensen, D., Holden, M., Connor, T. R., Loman, N., Goodfellow, I. G., Carrington, C., Templeton, K., Rambaut, A.
10.1101/2021.12.13.21267267 — Posted: 2021-12-14
COVID-19 in French Nursing Homes during the Second Pandemic Wave: A Mixed-Methods Cross-Sectional Study
Dujmovic, M., Roederer, T., Frison, S., Melki, C., Lauvin, T., Grellety-Bosviel, E.
10.1101/2021.12.12.21267681 — Posted: 2021-12-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).